Amarin (AMRN) vs DiaMedica Therapeutics (DMAC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
DiaMedica Therapeutics (DMAC) has outperformed Amarin (AMRN) over the past year, gaining 8.1% versus a loss of 35.5%. Over five years, DMAC leads with a +118.8% price change compared with -85.5% for AMRN. DiaMedica Therapeutics is the larger company by market cap ($445.1 million vs $444.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMRN | DMAC |
|---|---|---|
| Share price | $10.57 | $8.25 |
| Market cap | $444.39M | $445.15M |
| 1-day change | -6.13% | +2.87% |
| YTD return | -24.28% | +3.64% |
| 1-year return | -35.47% | +8.13% |
| 5-year return | -85.48% | +118.83% |
| Forward P/E | 10.79 | — |
| EPS (TTM) | $-0.80 | $-0.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $213.65M | — |
| Revenue growth (YoY) | -6.55% | — |
| Net income (latest FY) | $-38.80M | $-32.77M |
| Gross margin | 56.57% | — |
| Operating margin | -23.48% | — |
| Net margin | -18.16% | — |
| 52-week high | $17.31 | $11.00 |
| 52-week low | $10.56 | $5.25 |
| Distance from 52-week high | -38.94% | -25.00% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +22.99% | +96.97% |
| Average volume | 79.50K | 210.46K |
| Shares outstanding | 42.04M | 53.96M |
| Employees | 80 | 35 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DMAC has outperformed AMRN by 43.6 percentage points over the past year.
About Amarin
AMRN stock →Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 80 employees
About DiaMedica Therapeutics
DMAC stock →DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction.
Health Care · Biotechnology: Pharmaceutical Preparations · 35 employees
AMRN vs DMAC FAQ
Which is bigger, Amarin or DiaMedica Therapeutics?
DiaMedica Therapeutics (DMAC) is larger, with a market capitalization of $445.15M compared with $444.39M for Amarin (AMRN).
Which stock has performed better over the past year, AMRN or DMAC?
DMAC returned +8.13% over the past 12 months, compared with -35.47% for AMRN (price return, excluding dividends). Past performance does not predict future results.
Are Amarin and DiaMedica Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.